retatrutide gip glp-1 glucagon receptor agonist 40mg Pen | Triple G Weight Management | Premio Peptides GLP-1 Receptor Agonists | New

When a compound contacts this tissue and stays there long enough, it passes directly into the bloodstream without going through the stomach or liver first

Retatrutide Safety Profile Nausea: 16-25% (dose-dependent) Diarrhea: 16-22% Heart rate increase at higher doses Discontinuation: 6-10% Limited long-term safety data Tirzepatide Safety Profile Nausea: 12-24% (dose-dependent) Diarrhea: 12-18% No significant heart rate changes Discontinuation: 5-7% Extensive Phase 3 and real-world data GI side effects were broadly similar between the two compounds in their respective trials, though direct comparison is limited by different study designs

Yet, for many people, these DIY approaches dont lead to lasting results on their own

Understanding alternatives helps researchers make informed comparisons